CNS Bioscience, Inc. was founded by Scott Falci in 2013 as a drug development company. It’s president, chief executive officer and board member is Matthew Autterson. The company produces drug to mitigate the effects of neuropathic pain. CNS is short for Central Nervous System. CNS Biosciences, Inc. is an appropriate name for a company that focuses on developing treatment for neuropathic pain.
Matthew Autterson is a managing partner of GL3B Partners Limited, LLP, a business consulting firm located in Cherry Hills Village, Colorado. GL3B was founded in 2013. Autterson studied finance at Michigan State University. Today, Autterson is using his formal education and his extensive business experience to take Dr. Scott Falci’s CNS Biosciences to it first successful delivery of a new neuropathic medicine to the market.
Dr. Falci is a practicing neurological surgeon in Englewood, New Jersey. He has been practicing medicine for 26 years. He graduated from Georgetown University of Medicine in 1985 and today has his own practice and is associated with Craig Hospital and the Swedish Medical Center. He treats intervertebral disc degeneration and intracranial injuries. The procedures he most commonly utilizes to treat those problems are neurological testing, lumbar punctures, craniotomies, spinal fusion and spinal surgery.
Matthew Autterson joined forces with Dr. Falci and together they have a fighting chance of developing a ground-breaking medicine or treatment to fight one of the most insidious medical issues plaguing the health of many. Neuropathic pain is the culprit that causes suffering to patients diagnosed with cancer, diabetes, shingles and HIV. People suffering from nerve pain experience additional challenges as a result of the peripheral pain they feel. It could also cause sleeplessness, depression and anxiety. It could create life-changing challenges as the burning, pin pricks, electrical shocks and overall nerve pain disrupts the afflicted person’s existence. See This Page to learn more.
Autterson and Falci are tackling the problem of neuropathic nerve pain head on. With the creation of an effective medicine, those who suffer endlessly will finally get a reprieve from the constant pain. CNS Biosciences has a lot of competition to create a new treatment for nerve pain, but there are many sufferers, so there is room for more than one treatment. As always, the best treatment will make itself evident. CNS Biosciences has a good clinical leader in Dr. Falci and with the business leadership of Matthew Autterson, should soon produce a breakthrough that will change the faces of neuropathic pain sufferers in the world.
More on: https://angel.co/matthew-autterson